Dapagliflozin: An SGLT2i with Benefits on Glucose Control and Beyond

I. CATANIA: An SGLT2i with Benefits on Glucose Control and Beyond

DIABETES IN THE FILIPINO POPULATION

 

INSULIN-INDEPENDENT ACTION: ^6-7
Dapagliflozin does not rely on insulin and provides unique benefits

In summary: 
     - SGLT2i is the only anti-diabetic drug that is insulin-independent in its action.
     - It presents a triad of benefits: metabolic, renal and cardiac.
     - Diabetes and liver disease may co-occur. SGLT2i is safe and is preferred for treatment of T2D inpatients with MASLD.


II. SGLT2i: Dapagliflozin and Cardiovascular Benefits 

Sodium-glucose cotransporter 2 – inhibitors (SGLT2-i) Benefits:

Highlights of the DECLARE Trial 

DAPAGLIFLOZIN: GLYCEMIC AND WEIGHT-LOWERING EFFICACY¹⁰

HEART FAILURE OUTCOME BENEFITS^16-17

DAPAGLIFLOZIN in Heart Failure with or without T2D
Pooled data showed consistent beneficial effects across the entire range of left ventricular ejection fraction irrespectiveof timing of most recent heart failure hospitalization.

Heidenreich PA, et al.J Am Coll Cardiol. 10/1016/j.jacc.2021.12.012


III. SGLT2i: Dapagliflozin and Renal Benefits






Common in First 2-4 Weeks: eGFR drops by <30% (usually reversible)


Dapagliflozin's Renal Protection Pathways²¹



Patient Populations that Benefit from Dapagliflozin

IV. Cost-Effectiveness of Dapagliflozin for Heart Failure and CKD: Should We Care?

COST EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN HF

MARCOV Model
     - Dynamic mathematical models that simulate how a hypothetical cohort of individual's transition between health states over time.
     - Used to evaluate cost-effectiveness of a drug in treating a chronic disease.
     - Cost-utility analysis that used DAPA-HF as the basis of dapagliflozin’s efficacy.
     - Evaluated dapagliflozin in terms of CKD progression, cost-effectiveness and mortality. 






^{References: 1. Jimeno CA, Sobrepena L, Mirasol R. Phil Journal of Int Med 2012, 50 (1);15-262 2. Amiel SA, et al., Diab Med 2008;25:245-54 3. UK prospectiveDiab Study (UKPDS) Group. Lancet 1998;352:854-65 4. Weyer C, et al., J Clin Invest 1999; 104;787-94 5. Guisasiola AF, Diab Obes Metab 2008;10(Suppl.1):25-326. Wright EM, Am J Physiol Renal Physiol 2001; 280:F10-18 7. Gerich JE. Diabetes Obes Metab 2000;2:345-5024. 8. EASL-EASD-EASO GL. J. Hepatol, ObesityFacts, Diabetologia 2024;81(3):492-542. 9. Melmed, S., Koenig, R., Rosen, C. J., Auchus, R. J., & Goldfine, A. B. (Eds.). (2019). Williams Textbook of Endocrinology(14th ed.). Elsevier 10. Hinnen D. Ther Adv Endocrinol Metab. 2015;6(3):92-102. 11. Einarson TR, et al. Cardiovasc Diabetol. 2018;17:83; 12. Zinman B, et al.Article and online supplement. N Engl J Med. 2015;373:2117–2128; 13. Neal B, et al. N Engl J Med. 2017;377:644–657; 14. Raz I, et al. DiabetesObes Metab.2018;20:1102–1110; 15. Wiviott S, D et al. N Engl J Med. 2019;380:347-357. 16. McMurray JJV, et al. N Engl J Med. 2019;381(21):1995-2008. 17. Solomon SD,et al. N Engl J Med. 2022;387(12):1089-1098. 18. Dharia A, et al. Annu Rev Med. 2023;74:369-384. 19. Heerspink HJL, et al. N Engl J Med. 2020;383(15):1436-1446. 20. Meraz-Muñoz AY, et al. Kidney 360. 2021 Mar 26; 2(6): 1042-1047. 21. Heerspink HJL, Cherney DZI. Nephrol. 2021 Aug: 16(8): 1278 22. Mudaliar S., etal. Diabetes Care. 2016 Jul;39(7):1115-22 23. Bhatt AS et al. J Am Heart Assoc. 2024;13:e032279 24. Mendoza VL et al. ESC Heart Failure 2021; 8: 5132–5141}